MULTIPLE MYELOMA

During a live event, Samuel M. Rubinstein, MD, discussed the outcomes from the KarMMa-3 trial and real-world patients receiving ide-cel in terms of bridging therapy, quality of life, and prior BCMA therapy.

Combination therapy with BPd shows significant progression-free survival benefits in relapsed/refractory multiple myeloma patients with high-risk cytogenetic abnormalities.

During a live event, Taewoong Choi, MD, discussed the current state of therapy for transplant-ineligible newly diagnosed multiple myeloma.

JNJ-79635322 shows favorable responses and manageable safety in BCMA/GPRC5D-naïve patients with relapsed/refractory multiple myeloma.

Daratumumab enhances treatment efficacy in newly diagnosed multiple myeloma, showing improved MRD negativity and progression-free survival in recent clinical trials.

A phase 3 trial did not support a transplant-based approach for patients who already achieved MRD negativity or a tandem transplant approach for those who did not achieve prior MRD negativity.

A single cilta-cel infusion led to 33% of heavily pretreated relapsed/refractory multiple myeloma patients remaining progression-free at 5+ years.

Extended follow-up of MonumenTAL-1 shows talquetamab-tgvs yields durable ORRs and promising survival outcomes in relapsed/refractory multiple myeloma, with a tolerable safety profile.

During a live event, Konstantinos Sdrimas, MD, asked participants what community oncologists should consider when referring patients for CAR T-cell therapy.

During a live event, Samuel M. Rubinstein, MD, discussed the efficacy and safety outcomes from the KarMMa-3 trial.

During a live event, Naresh Bumma, MD, discussed CRS, oral and skin toxicities, and low discontinuation rates with talquetamab in multiple myeloma.

In a 6 to 2 vote, the Oncologic Drug Advisory Committee determined that findings from the phase 3 AQUILA trial do support a positive benefit-risk ratio for patients with smoldering multiple myeloma.

In an interview with Targeted Oncology, C. Ola Langren, MD, PhD, discussed the continuing impact of the groundbreaking FDA ODAC vote, the future of the Miami Myeloma MRD Meeting, and how researchers plan to continue expanding the role of MRD in myeloma and other hematologic malignancies.

Ashraf Z. Badros, MBChB, discussed the results from the AURIGA trial of maintenance therapy with daratumumab and lenalidomide in newly diagnosed multiple myeloma.

In the last year, there has been excitement about the use of MRD in multiple myeloma trials and new approaches to assessing clinical outcomes in patients.

In separate live virtual events, Sarah A. Holstein, MD, PhD, and Shashank Cingam, MD, discuss options for a patient with relapsed/refractory multiple myeloma and the use of chimeric antigen receptor (CAR) T-cell therapy.

During a live event, Jack Khouri, MD, discusses selinexor-based therapies for relapsed multiple myeloma, emphasizing AE management and weekly dosing.

During a live event, Kathleen A. Dorritie, MD, discussed updated outcomes from the IsKia, MASTER, and CONCEPT clinical trials of frontline therapy in multiple myeloma.

Following promising phase 1 data, ISB 2001 has gained fast track designation from the FDA for the treatment of relapsed/refractory multiple myeloma.

The final ALCYONE analysis with 86.7-month follow-up shows daratumumab-VMP significantly improved overall survival in transplant-ineligible, newly diagnosed multiple myeloma.

Douglas Sborov, MD, discusses adverse events in the MajesTEC-1 study of teclistamab in multiple myeloma.

During a live event, Naresh Bumma, MD, discussed talquetamab’s efficacy in relapsed/refractory multiple myeloma, including high-risk patients.

During a live event, Jack Khouri, MD, discussed options for patients with multiple myeloma after relapse and choices to consider before CAR T-cell therapy.